Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) granted non‑statutory stock options to one new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The company awarded 34,000 options at an exercise price of $7.81 per share (closing price on March 2, 2026).

The options carry a 10‑year term and vest over four years: 25% on the first anniversary of employment, then 6.25% quarterly over the following 12 quarters, subject to continued service. The award was made pursuant to the company’s 2022 Inducement Stock Incentive Plan.

Key Figures

Inducement options: 34,000 options Exercise price: $7.81 per share Option term: 10 years +5 more

8 metrics

Inducement options 34,000 options Grant to one new employee under 2022 Inducement Plan

Exercise price $7.81 per share Closing price on grant effective date, March 2, 2026

Option term 10 years Non-statutory stock options issued as inducement grant

Initial vesting 25% of shares Vests on first anniversary of employee’s start date

Ongoing vesting 6.25% quarterly Equal installments over twelve quarters after first anniversary

Current price $8.17 Price before release, down 2.28% over prior 24 hours

52-week range $2.315–$15.7399 Price 48.09% below 52-week high; 252.92% above low

Market cap $543,457,705 Equity value prior to this inducement grant announcement

Market Reality Check

Price: $7.94 Vol: Volume 767,290 vs 20-day ...

low vol

$7.94 Last Close

Volume Volume 767,290 vs 20-day avg 1,146,382 (relative volume 0.67x) before this filing. low

Technical Price $8.17 trades below 200-day MA at $8.74, indicating a pre-existing downtrend.

Peers on Argus

Argus momentum data flags a sector move, with 2 biotech peers (including PRTC) m...

2 Down

Argus momentum data flags a sector move, with 2 biotech peers (including PRTC) moving down (median about -3.6%) on the day, suggesting broader biotech pressure alongside FULC’s modest -2.28% decline.

Common Catalyst One close peer, SLDB, reported a sizeable private placement and conference participation, while other peers moved mainly on sector dynamics rather than company-specific headlines.

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Conference participation	Neutral	+0.8%	Announcement of participation in Leerink Partners Global Healthcare Conference.
Feb 24	Earnings & update	Positive	-21.2%	Fourth quarter 2025 results with positive PIONEER data and strong cash runway.
Feb 24	Clinical trial data	Positive	-21.2%	Positive 12-week Phase 1b PIONEER 20 mg cohort data in sickle cell disease.
Feb 17	Data presentation plan	Neutral	+0.3%	Scheduling of 12-week PIONEER trial data presentation webcast.
Feb 06	Inducement option grant	Neutral	+5.0%	Inducement grant of 70,000 options under 2022 Inducement Stock Incentive Plan.

Pattern Detected

Recent history shows sharp negative reactions around positive clinical/earnings updates, while neutral items such as conferences and inducement grants have seen modestly positive moves.

Recent Company History

Over the past month, Fulcrum reported multiple milestones, including positive Phase 1b PIONEER data and 2025 financial results, yet those updates on Feb 24, 2026 saw about -21% moves. Neutral communications like conference participation (Mar 3, 2026) and prior inducement grants (Feb 6, 2026) produced small gains. Today’s Nasdaq Rule 5635(c)(4) inducement option grant continues that pattern of routine equity-based compensation alongside a stock trading well below its 52-week high.

Market Pulse Summary

This announcement details a standard inducement grant of 34,000 stock options at an exercise price o...

Analysis

This announcement details a standard inducement grant of 34,000 stock options at an exercise price of $7.81 under Nasdaq Listing Rule 5635(c)(4), adding modest equity-based compensation to Fulcrum’s structure. In recent months, the company has reported positive PIONEER clinical data and a substantial cash position through 2029, yet those updates triggered sharp price swings. Investors monitoring Fulcrum’s trajectory may focus on future clinical milestones, additional equity awards, and any changes in insider trading patterns or major filings.

Key Terms

nasdaq listing rule 5635(c)(4), non-statutory stock options, exercise price, vesting, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock options financial

"announced that the company granted non-statutory stock options to one new employee"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

exercise price financial

"34,000 options to purchase shares ... at an exercise price of $7.81 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

stock incentive plan financial

"pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended"

A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employee 34,000 options to purchase shares of the company’s common stock at an exercise price of $7.81 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, March 2, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What exactly did Fulcrum (FULC) grant on March 2, 2026?

Fulcrum granted 34,000 non‑statutory stock options to a new employee as an inducement. According to the company, the options were priced at $7.81 per share, the closing price on the grant effective date of March 2, 2026.

What are the vesting terms for the FULC inducement grant?

The options vest over a four‑year schedule with 25% at year one and 6.25% quarterly thereafter. According to the company, vesting is subject to the employee’s continued service through each vesting date.

How long is the exercise period for the FULC options awarded in March 2026?

The options have a ten‑year term from the grant date. According to the company, the exercise period is ten years and the exercise price equals the closing share price on the grant effective date.

Under what plan and Nasdaq rule were the FULC inducement options granted?

The award was made under the company’s 2022 Inducement Stock Incentive Plan in reliance on Nasdaq Listing Rule 5635(c)(4). According to the company, the grant was material to hiring the new employee.